Get the Stockscreener App
0.4002
6.65%
-0.0285
After Hours:
.39
-0.0102
-2.55%
Bioatla Inc stock is traded at $0.4002, with a volume of 225.02K.
It is down -6.65% in the last 24 hours and up +27.01% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$0.4287
Open:
$0.425
24h Volume:
225.02K
Relative Volume:
0.35
Market Cap:
$23.38M
Revenue:
-
Net Income/Loss:
$-123.46M
P/E Ratio:
-0.1545
EPS:
-2.59
Net Cash Flow:
$-104.11M
1W Performance:
-6.89%
1M Performance:
+27.01%
6M Performance:
-74.35%
1Y Performance:
-87.09%
1-Day Range:
$0.4002
$0.4304
1-Week Range:
$0.387
$0.493
52-Week Range:
$0.2601
$3.16
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.4002 | 25.11M | 0 | -123.46M | -104.11M | -2.59 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
BioAtla receives Nasdaq delisting warning By Investing.com - Investing.com Nigeria
BioAtla receives Nasdaq delisting warning - Investing.com Australia
BioAtla Receives Nasdaq Non-Compliance Notice - TipRanks
HC Wainwright Issues Negative Estimate for BioAtla Earnings - Defense World
HC Wainwright Predicts BioAtla’s Q1 Earnings (NASDAQ:BCAB) - Defense World
BioAtla Inc (NASDAQ: BCAB): Is Its Value Too High Compared To Others? - Stocksregister
BioAtla stock holds $1 target, JMP affirms Market Outperform By Investing.com - Investing.com Nigeria
BioAtla at Citizens JMP Life Sciences: Strategic Partnerships in Focus By Investing.com - Investing.com India
BioAtla at Citizens JMP Life Sciences: Strategic Partnerships in Focus - Investing.com Australia
Bioatla Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Gaining Ground: BioAtla Inc (BCAB) Closes Lower at 0.48, Down -8.19 - DWinneX
BioAtla, Inc. (NASDAQ:BCAB) Q1 2025 Earnings Call Transcript - Insider Monkey
BioAtla Q1 2025 Earnings Call Transcript - MarketBeat
BioAtla Inc (BCAB) Q1 2025 Earnings Call Highlights: Promising Clinical Progress Amid Financial ... By GuruFocus - Investing.com Canada
BioAtla (NASDAQ:BCAB) vs. Novavax (NASDAQ:NVAX) Head-To-Head Comparison - Defense World
Bioatla, Inc. Earnings Call Highlights Clinical Success - TipRanks
BioAtla, Inc. Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: Bioatla beats Q1 2025 earnings expectations - Investing.com
BioAtla, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:BCAB) - Seeking Alpha
Earnings call transcript: Bioatla beats Q1 2025 earnings expectations By Investing.com - Investing.com UK
BioAtla (BCAB) Advances Cancer Treatment with Promising Study Results | BCAB Stock News - GuruFocus
BioAtla reports Q1 EPS (26c), consensus (29c) - TipRanks
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress - The Manila Times
BioAtla Reports Breakthrough: Cancer Drug Triples Survival Rate vs Standard Treatment in Lung Cancer Study - Stock Titan
BioAtla, Inc. (NASDAQ:BCAB) Shares Acquired by Renaissance Technologies LLC - Defense World
There is no doubt that BioAtla Inc (BCAB) ticks all the boxes. - Sete News
BioAtla Inc (BCAB) shows promising results - uspostnews.com
BioAtla Reveals Next-Gen Cancer Treatment Progress: Key Updates Coming at Citizens Conference - Stock Titan
BCAB: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
An Analysis of BioAtla Inc (BCAB)’s Potential Price Growth - knoxdaily.com
BioAtla Q1 2025 Earnings: Biotech Leader to Share Latest Cancer Treatment Progress on May 6 - Stock Titan
BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025 - Yahoo Finance
Bank of Montreal Can Sells 522,252 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla Inc (BCAB) Could Be Worth Considering For The Next Few Weeks - Stocksregister
BioAtla announces poster presentations at 2025 AACR meeting - TipRanks
How did BioAtla Inc (BCAB) fare last session? - uspostnews.com
BCAB’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
BioAtla (BCAB) to Showcase Innovative Cancer Research at 2025 Co - GuruFocus
BioAtla Announces Poster Presentations At The 2025 American Association For Cancer Research (Aacr) Annual Meeting - TradingView
BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
Cancer Treatment Breakthrough: BioAtla's Novel Drug Outperforms Standard Therapy in Multiple Cancers - Stock Titan
BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
BioAtla, Inc. to Present Phase 2 Trial Results of Ozuriftamab Vedotin at ASCO 2025 Annual Meeting - Nasdaq
New Phase 2 Cancer Drug Data: BioAtla's Head and Neck Cancer Treatment Results at ASCO 2025 - Stock Titan
BioAtla stock holds $1 target, Market Outperform rating By Investing.com - Investing.com Nigeria
BioAtla stock holds $1 target, Market Outperform rating - Investing.com Australia
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Norges Bank Makes New Investment in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla's SWOT analysis: oncology biotech's stock faces pivotal year - Investing.com
BioAtla’s SWOT analysis: oncology biotech’s stock faces pivotal year By Investing.com - Investing.com South Africa
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):